JW Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

JW Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.62M	Hold	388,392	–	–	3.95%	3
2025 Q4	$9.07M	Hold	388,392	–	–	2.95%	4
2025 Q3	$7.65M	Hold	388,392	–	–	3.67%	6
2025 Q2	$8.43M	Sell	388,392 -25,000	-6%	-$590K	4.15%	5
2025 Q1	$10M	Hold	413,392	–	–	5.68%	2
2024 Q4	$8.63M	Hold	413,392	–	–	4.1%	5
2024 Q3	$8.22M	Hold	413,392	–	–	3.71%	5
2024 Q2	$6.4M	Hold	413,392	–	–	2.64%	8
2024 Q1	$6.59M	Hold	413,392	–	–	2.41%	9
2023 Q4	$6.95M	Sell	413,392 -150,000	-27%	-$2.05M	3.97%	7
2023 Q3	$6.59M	Hold	563,392	–	–	2.85%	6
2023 Q2	$7.57M	Hold	563,392	–	–	2.76%	5
2023 Q1	$9.34M	Hold	563,392	–	–	3.58%	3
2022 Q4	$10.5M	Buy	+563,392	New	+$8.67M	4.31%	2

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JW Asset Management's CPRX Position: Q1 2026 in Review

JW Asset Management held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 388,392 shares worth $9.62M. The position accounts for 3.95% of the portfolio, ranked #3.

JW Asset Management first reported a position in CPRX in Q4 2022 and has held it in 14 quarters since. The position peaked at $10.5M in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

JW Asset Management held 388,392 shares of Catalyst Pharmaceutical worth $9.62M as of Q1 2026.
JW Asset Management left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up 3.95% of JW Asset Management's portfolio in Q1 2026, its #3 holding.
JW Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 14 quarters since.
JW Asset Management's Catalyst Pharmaceutical position peaked at $10.5M in Q4 2022.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on JW Asset Management's 13F filing for Q1 2026, filed 8 May 2026.